|
审核状态: Project audit state: |
通过审核 Successful |
|
注册号: Registration number: |
ChiCTR2500103689 |
|
最近更新日期: Date of Last Refreshed on: |
2025-06-04 09:26:34 |
|
注册时间: Date of Registration: |
2025-06-04 00:00:00 |
|
注册号状态: |
预注册 |
|
Registration Status: |
Prospective registration |
|
注册题目: |
激素替代周期冻胚移植前hCG注射对低LH高龄人群妊娠结局影响的随机对照研究 |
|
Public title: |
A Randomized Controlled Study on the Impact of hCG Injection Prior to Frozen Embryo Transfer in Hormone Replacement Therapy-Frozen-Thawed Cycles on Pregnancy Outcomes in Women of Advanced Maternal Age with Low LH Levels |
|
注册题目简写: |
|
|
English Acronym: |
|
|
研究课题的正式科学名称: |
激素替代周期冻胚移植前hCG注射对低LH高龄人群妊娠结局影响的随机对照研究 |
|
Scientific title: |
A Randomized Controlled Study on the Impact of hCG Injection Prior to Frozen Embryo Transfer in Hormone Replacement Therapy-Frozen-Thawed Cycles on Pregnancy Outcomes in Women of Advanced Maternal Age with Low LH Levels |
|
研究课题代号(代码): Study subject ID: |
|
|
在二级注册机构或其它机构的注册号: The registration number of the Partner Registry or other register: |
|
申请注册联系人: |
韩旭 |
研究负责人: |
韩旭 |
|
Applicant: |
Xu Han |
Study leader: |
Xu Han |
|
申请注册联系人电话: Applicant telephone: |
+86 156 6845 0310 |
研究负责人电话:
Study leader's |
+86 156 6845 0310 |
|
申请注册联系人传真 : Applicant Fax: |
研究负责人传真: Study leader's fax: |
||
|
申请注册联系人电子邮件: Applicant E-mail: |
hanxu@sduivf.com |
研究负责人电子邮件: Study leader's E-mail: |
hanxu@sduivf.com |
|
申请单位网址(自愿提供): Applicant website(voluntary supply): |
研究负责人网址(自愿提供): Study leader's website(voluntary supply): |
||
|
申请注册联系人通讯地址: |
山东省济南市经六路157号山东大学附属生殖医院 |
研究负责人通讯地址: |
山东省济南市经六路157号山东大学附属生殖医院 |
|
Applicant address: |
Center for Reproductive Medicine, Shandong University.157 Jingliu Road, Jinan, Shandong Province, China |
Study leader's address: |
Center for Reproductive Medicine, Shandong University.157 Jingliu Road, Jinan, Shandong Province, China |
|
申请注册联系人邮政编码: Applicant postcode: |
研究负责人邮政编码: Study leader's postcode: |
||
|
申请人所在单位: |
山东大学附属生殖医院 |
||
|
Applicant's institution: |
Center for Reproductive Medicine, Shandong University. |
||
|
研究负责人所在单位: |
山东大学附属生殖医院 |
||
|
Affiliation of the Leader: |
Center for Reproductive Medicine, Shandong University. |
||
|
是否获伦理委员会批准: |
是 |
||
|
Approved by ethic committee: |
Yes |
||
|
伦理委员会批件文号: Approved No. of ethic committee: |
[2024]伦审字(71)号 |
伦理委员会批件附件: Approved file of Ethical Committee: |
查看附件View |
|
批准本研究的伦理委员会名称: |
山东大学附属生殖医院生殖医学伦理委员会 |
||
|
Name of the ethic committee: |
Institutional Review Board (IRB) of the Center for Reproductive Medicine, Shandong University |
||
|
伦理委员会批准日期: Date of approved by ethic committee: |
2024-05-10 00:00:00 | ||
|
伦理委员会联系人: |
王月婷 |
||
|
Contact Name of the ethic committee: |
Yueting Wang |
||
|
伦理委员会联系地址: |
山东省济南市经六路157号山东大学附属生殖医院 |
||
|
Contact Address of the ethic committee: |
Center for Reproductive Medicine, Shandong University.157 Jingliu Road, Jinan, Shandong Province, China |
||
|
伦理委员会联系人电话: Contact phone of the ethic committee: |
+86 531 8565 1376 |
伦理委员会联系人邮箱: Contact email of the ethic committee: |
|
|
研究实施负责(组长)单位: |
山东大学附属生殖医院 |
||||||||||||||||||||||
|
Primary sponsor: |
Center for Reproductive Medicine, Shandong University. |
||||||||||||||||||||||
|
研究实施负责(组长)单位地址: |
山东省济南市经六路157号山东大学附属生殖医院 |
||||||||||||||||||||||
|
Primary sponsor's address: |
Center for Reproductive Medicine, Shandong University.157 Jingliu Road, Jinan, Shandong Province, China |
||||||||||||||||||||||
|
试验主办单位(项目批准或申办者): Secondary sponsor: |
|
||||||||||||||||||||||
|
经费或物资来源: |
单位自筹 |
||||||||||||||||||||||
|
Source(s) of funding: |
Self-raised funds by the unit |
||||||||||||||||||||||
|
研究疾病: |
不孕症 |
||||||||||||||||||||||
|
Target disease: |
Infertility |
||||||||||||||||||||||
|
研究疾病代码: |
|
||||||||||||||||||||||
|
Target disease code: |
|
||||||||||||||||||||||
|
研究类型: |
干预性研究 |
||||||||||||||||||||||
|
Study type: |
Interventional study |
||||||||||||||||||||||
|
研究所处阶段: |
其它 | ||||||||||||||||||||||
|
Study phase: |
N/A |
||||||||||||||||||||||
|
研究设计: |
随机平行对照 |
||||||||||||||||||||||
|
Study design: |
Parallel |
||||||||||||||||||||||
|
研究目的: |
通过对HRT-FET周期孕酮转化子宫内膜前LH低水平高龄患者进行随机分组,同时研究组在孕酮转化内膜前一日注射hCG来进行干预,对两组患者的妊娠结局进行比较,以寻找改善高龄不孕人群体外助孕妊娠结局的治疗方案,为高龄不孕女性带来更多的生育希望。 |
||||||||||||||||||||||
|
Objectives of Study: |
A randomized grouping was conducted among patients of advanced maternal age with low LH levels, who were undergoing hormone replacement therapy-frozen embryo transfer (HRT-FET) cycles prior to progesterone administration. The study group additionally received an hCG injection one day before progesterone administration as an interventional measure. Subsequently, the pregnancy outcomes of the two groups were compared to investigate a treatment regimen that could improve the pregnancy success rates of in vitro fertilization (IVF) among elderly infertile populations, ultimately providing greater fertility hope to elderly infertile women. |
||||||||||||||||||||||
|
药物成份或治疗方案详述: |
|
||||||||||||||||||||||
|
Description for medicine or protocol of treatment in detail: |
|
||||||||||||||||||||||
|
纳入标准: |
1.IVF或ICSI周期有冷冻囊胚,准备冻胚移植;2.年龄≥35岁、≤42岁;3.内膜转化前LH<10IU/L、E2≥100pg/ml;4.内膜转化前厚度≥7mm。 |
||||||||||||||||||||||
|
Inclusion criteria |
1. Frozen blastocysts from IVF or ICSI cycles, ready for frozen embryo transfer 2. Age: >=35 years old and <=42 years old 3. LH < 10IU/L and E2 >= 100pg/ml before progesterone administration 4. Endometrial thickness >=7mm before progesterone administration |
||||||||||||||||||||||
|
排除标准: |
1.既往>2次胚胎移植失败史(包括未孕及生化妊娠流产);2.既往≥ 2次自然流产史;3.卵母细胞捐赠周期或胚胎植入前遗传学检测周期;4.子宫解剖结构异常、严重的子宫腺肌病、未处理的宫腔粘连等;5.未处理的输卵管积水。 |
||||||||||||||||||||||
|
Exclusion criteria: |
1.Previous history of more than 2 failed embryo transfers (including non-pregnancy and biochemical pregnancy losses); 2. Previous history of >= 2 spontaneous miscarriages; 3. Oocyte donation cycle or pre-implantation genetic testing cycle; 4.Abnormal uterine anatomy, severe adenomyosis, untreated intrauterine adhesions, etc.; 5.Untreated hydrosalpinx. |
||||||||||||||||||||||
|
研究实施时间: Study execute time: |
从 From 2025-01-01 00:00:00至 To 2026-12-31 00:00:00 |
征募观察对象时间: Recruiting time: |
从 From 2025-06-15 00:00:00 至 To 2026-12-31 00:00:00 |
|
干预措施: Interventions: |
|
|
研究实施地点: Countries of recruitment and research settings: |
|
||||||||||||||||||||||||||||
|
测量指标: Outcomes: |
|
|
采集人体标本:
Collecting sample(s)
|
|
|
征募研究对象情况: Recruiting status: |
尚未开始 Not yet recruiting |
年龄范围: Participant age: |
|
||||||
|
性别: |
女性 |
Gender: |
Female |
||||||
|
随机方法(请说明由何人用什么方法产生随机序列): |
随机数字表法 |
||||||||
|
Randomization Procedure (please state who generates the random number sequence and by what method): |
Random Number Table Method |
||||||||
|
是否公开试验完成后的统计结果: Calculated Results after the Study Completed public access: |
公开/Public |
|
盲法: |
单盲,对患者施盲 |
|
Blinding: |
Single-blind, with blinding of patients |
|
试验完成后的统计结果(上传文件): |
|
|
Calculated Results after
|
|
|
是否共享原始数据: IPD sharing |
是Yes |
|
共享原始数据的方式(说明:请填入公开原始数据日期和方式,如采用网络平台,需填该网络平台名称和网址): |
原始数据在研究结束相关论文发布后公布,可联系研究人员索要原始数据(邮箱hanxu@sduivf.com) |
|
The way of sharing IPD”(include metadata and protocol, If use web-based public database, please provide the url): |
The raw data will be made available upon the completion of the study and the publication of the associated paper. For access to the raw data, please contact the researcher via email at hanxu@sduivf.com. |
|
数据采集和管理(说明:数据采集和管理由两部分组成,一为病例记录表(Case Record Form, CRF),二为电子采集和管理系统(Electronic Data Capture, EDC),如ResMan即为一种基于互联网的EDC: |
根据试验方案设计CRF,确保涵盖所有需收集的指标,填写CRF数据基于原始病历,受试者访视后3个工作日内完成数据录入,通过双人录入、逻辑核查减少错误。 |
|
Data collection and Management (A standard data collection and management system include a CRF and an electronic data capture: |
The Case Record Form (CRF) is designed according to the trial protocol to ensure it covers all necessary data collection metrics. CRF data is filled out based on the original medical records, and data entry must be completed within 3 working days after the subject's visit. Errors are minimized through double data entry and logical checks. |
|
数据与安全监察委员会: Data and Safety Monitoring Committee: |
暂未确定/Not yet |